These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 26308228)
41. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States. Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177 [TBL] [Abstract][Full Text] [Related]
42. Gastrointestinal events and association with initiation of treatment for osteoporosis. Modi A; Siris ES; Tang J; Sajjan S; Sen SS Clinicoecon Outcomes Res; 2015; 7():603-13. PubMed ID: 26648746 [TBL] [Abstract][Full Text] [Related]
43. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. Anastasilakis AD; Goulis DG; Kita M; Avramidis A Hormones (Athens); 2007; 6(3):233-41. PubMed ID: 17724008 [TBL] [Abstract][Full Text] [Related]
44. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population. Buono JL; Mathur K; Averitt AJ; Andrae DA J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443 [TBL] [Abstract][Full Text] [Related]
45. Understanding the long-term impact of incident osteoporotic fractures on healthcare utilization and costs in Korean postmenopausal women. Han S; Kim S; Yeh EJ; Suh HS Osteoporos Int; 2024 Feb; 35(2):339-352. PubMed ID: 37878064 [TBL] [Abstract][Full Text] [Related]
46. Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea. Jung SY; Sohn HS; Park EJ; Suh HS; Park JW; Kwon JW PLoS One; 2016; 11(3):e0150531. PubMed ID: 26937968 [TBL] [Abstract][Full Text] [Related]
47. Rationale and design of MUSIC OS-EU: an international observational study of the treatment of postmenopausal women for osteoporosis in Europe and Canada. Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Nguyen AM; Keown PA; Leung AT; Sajjan S Clin Exp Rheumatol; 2015; 33(4):537-44. PubMed ID: 26146786 [TBL] [Abstract][Full Text] [Related]
48. Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates. Baillargeon J; Kuo YF; Lin YL; Wilkinson GS; Goodwin JS Ann Pharmacother; 2011 Oct; 45(10):1199-206. PubMed ID: 21954448 [TBL] [Abstract][Full Text] [Related]
49. Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density. RodrÃguez AJ; Ernst MT; Nybo M; Prieto-Alhambra D; Ebeling PR; Hermann AP; Abrahamsen B J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32717068 [TBL] [Abstract][Full Text] [Related]
50. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Layton D; Hughes K; Harris S; Shakir SA Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929 [TBL] [Abstract][Full Text] [Related]
51. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248 [TBL] [Abstract][Full Text] [Related]
52. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Taggart H; Bolognese MA; Lindsay R; Ettinger MP; Mulder H; Josse RG; Roberts A; Zippel H; Adami S; Ernst TF; Stevens KP Mayo Clin Proc; 2002 Mar; 77(3):262-70. PubMed ID: 11888030 [TBL] [Abstract][Full Text] [Related]
53. Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses. Mehta D; Davis M; Epstein AJ; Wensel B; Grinnell T; Williams GR Neurol Ther; 2020 Dec; 9(2):585-598. PubMed ID: 32949379 [TBL] [Abstract][Full Text] [Related]
54. Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs. Rahme E; Joseph L; Kong SX; Watson DJ; Pellissier JM; LeLorier J Pharmacoeconomics; 2001; 19(5 Pt 2):577-88. PubMed ID: 11465302 [TBL] [Abstract][Full Text] [Related]
55. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population. Grabner M; Peng X; Geremakis C; Bae J J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969 [TBL] [Abstract][Full Text] [Related]
56. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005 [TBL] [Abstract][Full Text] [Related]
57. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States. Lu M; Oladapo A; Wu Y; Farahbakhshian S; Ewenstein B J Manag Care Spec Pharm; 2021 Feb; 27(2):175-185. PubMed ID: 33307935 [No Abstract] [Full Text] [Related]
58. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States. Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794 [TBL] [Abstract][Full Text] [Related]
59. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968 [TBL] [Abstract][Full Text] [Related]
60. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. Green J; Czanner G; Reeves G; Watson J; Wise L; Beral V BMJ; 2010 Sep; 341():c4444. PubMed ID: 20813820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]